Prot #CA209-8Y8: A Phase 3b, Randomized, Double-blind Study of Nivolumab Combined with Ipilimumab versus Nivolumab Monotherapy for Patients with Previously Untreated Advanced Renal Cell Carcinoma and Intermediate- or Poor-Risk Factors

Project: Research project

Project Details

StatusActive
Effective start/end date2/5/202/5/23

Funding

  • Bristol-Myers Squibb Company (Prot #CA209-8Y8)